Supplementary Table S1. Trifluridine/tipiracil exposure and management (*n*=379)

Treatment characteristics	Value
Planned dose at first cycle (mg/m^2, twice a day), median (IQR)[a]	35.0 (35.0-35.0)
Treatment modification, *n* (%)	
Dose reduction	116 (30.6)
Due to toxicity[b]	108 (28.5)
Due to general state impairment	6 (1.5)
Due to other reasons	2 (0.5)
Dose delay	191 (50.4)
Due to toxicity[c]	167 (44.1)
Due to general state impairment	11 (2.9)
Due to other reasons	32 (8.4)
Reasons for end of treatment, *n* (%)	
Disease progression	300 (79.2)
General state impairment	48 (12.7)
Toxicity[d]	17 (4.5)
Patient decision	7 (1.8)
Other reasons	7 (1.8)
Total number of administered cycles, median (IQR)	3.0 (2.0-4.0)[e]

IQR interquartile range.

[a]The planned dose at the first cycle was <35 mg/m^2 in 8 patients: 25 mg/m^2 *n*=1, and 30 mg/m^2 *n*=7.

[b]These 108 patients had 137 dose reductions due to the following toxicities: neutropaenia *n*=94, asthenia *n*=18, diarrhoea *n*=17, anaemia *n*=16, anaemia/thrombopaenia *n*=9, thrombopaenia *n*=5, bilirubin increase *n*=3, nausea/vomiting *n*=3, leucopaenia *n*=2, vomiting *n*=2, lymphocytopaenia *n*=1, mucositis *n*=1, nausea *n*=1, pancytopaenia *n*=1, and sickness/vomiting *n*=1 (multiple response variable, there may be more than one toxicity for each reduced dose).

[c]These 167 patients had 247 dose delays due to the following toxicities: neutropaenia *n*=197, anaemia *n*=25, diarrhoea *n*=13, asthenia *n*=12, thrombopaenia *n*=6, bilirubin increase *n*=5, leucopaenia *n*=2, nausea *n*=2, alkaline phosphatase *n*=1, alopecia *n*=1, anaemia/thrombopaenia *n*=1, bacterial infection *n*=1, fever *n*=1, liver

toxicity *n*=1, and vomiting *n*=1 (multiple response variable, there may be more than one toxicity for each delayed dose).

[d]These 17 patients reported end of treatment due to the following toxicities: neutropaenia *n*=6, anaemia *n*=3, diarrhoea *n*=2, asthenia *n*=2, anorexia *n*=1, atrial fibrillation *n*=1, cardiac toxicity *n*=1, impaired kidney function *n*=1, liver toxicity *n*=1, lumbalgia *n*=1, nausea *n*=1, pancytopaenia *n*=1, urinary tract infections favoured by neutropaenia *n*=1 (multiple response variable, there may be more than one toxicity for each ended treatment).

[e]Missing data *n*=1.